Initially reported as an arcane behaviour of bacterial populations, microbial biofilm formation is now recognized as a principle virulence factor in many localized chronic infections. Biofilm infections commonly recur after long periods of clinical quiescence. This is not primarily due to genetic resistance that arises by mutation, although the increased microbial cell density may favour the transfer of resistance genes. Rather, microorganisms that reside in biofilms may develop tolerance to traditional antibiotics or antimicrobial agents through metabolic dormancy or molecular persistence programmes. Moreover, the important role of the extracellular matrix in conferring antimicrobial tolerance to biofilms is being recognized 1 . Advances in multi-omic and imaging technologies have also revealed the remarkable complexity and spatial organization of polymicrobial biofilm infections 2 . Accordingly, our increased understanding of biofilms is rapidly chan ging the strategies that are used to treat these challenging infections (FIG. 1) . Nonetheless, the control of biofilm formation and treating existing biofilms remains tenuous, with few new therapeutic options currently available clinically.
Biofilm infections are not easily amenable to existing antimicrobial treatment or single 'magic bullet' approaches, because biofilm recalcitrance is a consequence of complex physical and biological properties with multiple microbial genetic and molecular factors, and they frequently involve multi-species interactions. A diverse range of microorganisms (Gram-positive and Gram-negative, motile and non-motile, aerobic, anaerobic and facultative bacteria, and fungi) form biofilms, which share many common features
. Although the 'universal' role of cell signalling in biofilm formation was revealed 20 years ago, signalling-based therapeutics have yet to be introduced for the clinical management of biofilm infections owing to the complexity of cell signalling networks. Similarly, the emergence of materials science, including the development of surface modifications that incorporate technologies that target adhesion, as well as biomimicry or surface textures and chemistries from plants and animals 3 , were promising approaches to prevent microbial adherence and subsequent biofilm formation. Although many studies show statistically significant reductions in biofilm or alterations in biofilm structures in the laboratory, few were tested or validated using in vivo or human cell models to see whether they translated to clinical significance. Many studies only report early time points, fail to use clinically relevant treatment regimens or do not consider the presence of molecularly complex host fluids or host cells at the site of biofilm infections. More recent approaches include targeting the extracellular polymeric substance (EPS) matrix. However, the variability in the composition of the EPS matrix and the interactions among the various components 4 add new levels of complexity and provide challenges for the development of EPS-targeting therapeutics 5 . Several excellent reviews discuss how microorganisms develop pathogenic biofilms and their protective mechanisms against antibiotics, antimicrobial agents and host innate immunity 1, 6, 7 . This Review focuses on the challenges that face the development of biofilmspecific therapeutic strategies, how new insights into Targeting microbial biofilms: current and prospective therapeutic strategies Hyun Koo 1 , Raymond N. Allan 2, 3 , Robert P. Howlin 4, 5 , Paul Stoodley [6] [7] [8] and Luanne Hall-Stoodley 5, 6 Abstract | Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections. The multifactorial nature of biofilm development and drug tolerance imposes great challenges for the use of conventional antimicrobials and indicates the need for multi-targeted or combinatorial therapies. In this Review, we focus on current therapeutic strategies and those under development that target vital structural and functional traits of microbial biofilms and drug tolerance mechanisms, including the extracellular matrix and dormant cells. We emphasize strategies that are supported by in vivo or ex vivo studies, highlight emerging biofilm-targeting technologies and provide a rationale for multi-targeted therapies aimed at disrupting the complex biofilm microenvironment.
the chemical composition and structure of the EPS matrix, active biofilm dispersal pathways, and a recognition of the role of dormant cells -or persisters -or slow-growing subpopulations in conferring antibiotic tolerance are being used to target biofilm infections. We also review developing technologies that promise to enhance the efficacy of current modalities or provide novel biofilm-targeting effects, including challenges to ensure biocompatibility and therapeutic efficacy, both of which are crucial for clinical translatability. Where possible, we focus on technologies that have shown efficacy in preclinical trials or on robust animal or human cell infection models. However, as not all potential biofilm-targeting therapeutic strategies can be discussed in detail, we provide a comprehensive list of current and prospective biofilm-targeting strategies, their developmental stage and a brief list of advantages and disadvantages in Supplementary information S1 (table) .
Finally, we contend that treating biofilm infections requires combination therapies or those that target more than one component of the complex biofilm microenvironment, similar to the treatment of cancer 8 . Importantly, biofilm infections reflect an interplay between the host and opportunistic pathogens, often within a complex microbiota. Polymicrobial biofilms pose an additional challenge, requiring antimicrobials that are effective against all pathogenic microorganisms in the biofilm and limiting the efficacy of species-specific biofilm-targeting strategies. All of these challenges contribute to the reason why so few therapies have yet to be translated clinically.
Current therapeutic approaches
Many biofilm management strategies currently being devised in the clinic and used by surgeons are largely based on an approach from cancer treatment
: early and aggressive physical removal and local delivery of high and sustained antimicrobial chemotherapy 9 . Given the devastating consequences if a biofilm infection persists, surgeons are undertaking earlier and more aggressive treatment, including revisiting 'old' last-resort antibiotics, such as colistin 10 . Another established approach used for intravenous catheterrelated infections is lock therapy 11 . Following a decision to treat rather than remove certain types of catheters, the potential to leave biofilms intact (but containing dead cells) includes the potential to promote colonization by other microorganisms. This illustrates a crucial point regarding biofilms: killing does not necessarily eradicate the biofilm. Therefore, the challenge of using antimicrobial agents, which may kill microorganisms but leave behind other biofilm components, must be addressed.
As understanding the mechanisms of biofilm formation derives primarily from how they form on solid surfaces, most clinical trials that test biofilmtargeting approaches or FDA-approved therapeutics have focused on indwelling medical devices. Current biofilm-targeting technologies can be divided into two groups: physical-mechanical approaches (for example, high-velocity spray and jet irrigators) that are aimed at biofilm disruption and removal; and surface-coating or eluting substrates. Coatings or substrates can be impregnated with anti biotics and/or antimicrobials (for example, acrylic beads with absorbable antibiotic-loaded bone cement to prevent orthopaedic infection 12 ) for biofilm prevention, whereby higher localized antibiotic concentrations can be achieved for longer periods of time with in situ antibiotic delivery compared with systemic administration. Several antimicrobial metal or inorganic coatings have also reached clinical application to prevent biofilm formation 13 . These include silver coating in endotracheal tubes, catheters, megaprostheses, wound dressings and copper alloys in hospital surfaces (Supplementary information S1 (table) ). With respect to treating pre-existing biofilms, laboratory studies show that statistically significant reductions in biofilm viability can require extended incubation periods with high concentrations of antibiotic. In situ release provides an important approach to achieve such high concentrations over long treatment periods 14, 15 . Although antibioticimpregnated beads in bone cements or dental restorative materials were used before biofilm formation was recognized as a distinct aetiological factor, they represent a class of technologies that are now being re-examined to gain a better understanding of their effect in controlling biofilm infections 16 . Mechanical disruption using water sprays and jets has been developed and used for pathogenic biofilm removal and for irrigation, including debridement of surgical-site infections to remove necrotic tissue, exudates or dental biofilms. High-speed imaging has provided important information on fluid-biofilm-surface interactions and shows that although a statistically significant amount of biofilm is removed from the area, the biofilm becomes fluidized and spreads across the surface 17 . The ability of biofilms to become fluidized probably explains the tenacity of bacteria on surfaces after pulsed lavage 18 and may contribute to the low success rate of irrigation and debridement alone in treating periprosthetic infections. An advantage of water-based jets is that antimicrobial agents can be readily added so that the fluid doubles as a delivery device as well as creating mechanical forces acting on the biofilm. However, despite advances in biofilm-specific clinical therapies, particularly for indwelling devices, most approaches still entail conventional antibiotic-based therapy or topical broad-spectrum antimicrobials.
EPS-targeting strategies
The composition of the EPS matrix is temporally and structurally variable, depending on the type of microorganism, local mechanical shear forces, substrate availability and the host environment. The EPS matrix promotes microbial adherence to a surface, cell-cell adhesion and aggregation 19 , and functions as a 3D scaffold that provides cohesiveness, mechanical stability and protection against host effectors and antimicrobial therapies. In addition, the EPS matrix can dynamically modulate chemical and nutrient gradients and delineate pathogenic environments (such as acidic pH and hypoxia), which contribute to key virulence attributes, including recalcitrance 1, 4 . Thus, targeting the EPS matrix may be an effective strategy to remove biofilms, disaggregate bacteria and disrupt the pathogenic environment 20 . Targeting can be achieved by inhibiting the production of EPS, binding EPS adhesins on the microbial surfaces to block adhesion or by degrading EPS in established biofilms (FIG. 2) .
Disrupting EPS synthesis and secretion, and the binding of EPS adhesins. Several extracellular and intracellular signalling networks, as well as non-signalling mechanisms that promote the production of EPS, have been identified. In general, cyclic-di-GMP (c-di-GMP) and cyclic-di-AMP (c-di-AMP) 21 control various EPSproducing exoenzymes, polysaccharides and adhesins that are potential candidates that can be targeted to inhibit or disrupt the EPS 22, 23 . These nucleotide-signalling molecules regulate glucan-producing exoenzymes (for example, glucosyltransferase) in the Gram-positive bacterium Streptococcus mutans, as well as the aggregative exopolysaccharides Psl and Pel in the Gram-negative Pseudomonas aeruginosa. Several potential smallmolecule inhibitors of di-guanylate or di-adenylyl cyclase have been identified through library screening or in silico drug discovery combined with bioactivity assessment using in vitro biofilm models 24, 25 , although their efficacy against biofilms awaits further in vivo validation.
The inhibition of EPS glucan synthesis by glucosyltransferase using small-molecule inhibitors decreased the accumulation of pathogenic biofilms on teeth and supressed the onset of oral diseases in vivo without disturbing the resident microbiota 26, 27 . These smallmolecule inhibitors alone are not superior to current chemical modalities for oral biofilm control (chlorhexidine) or tooth decay prevention (fluoride); however, when used in combination, EPS inhibitors can greatly enhance their therapeutic effects 26 . Inhibitors of adhesin production and adhesin-binding antibodies or peptides have also been developed to disrupt bacterial binding to host surfaces. Small molecules (for example, peptides or mannosides) that target host-EPS inter actions have shown efficacy in prevention and treatment of both bacterial and fungal biofilm infections in vivo 28, 29 .
Mannosides that target the bacterial adhesin FimH (alone or combined with trimethoprim-sulfamethoxazole) prevented catheter-associated urinary tract infection (UTI) in mice by reducing Escherichia coli colonization by 2 logs and treated chronic cystitis by reducing the Biofilm formation proceeds as a developmental process with distinct stages: 'initial adhesion', in which microorganisms adhere to a host or attach to medical device surfaces through cell-surface-associated adhesins; 'early biofilm formation', whereby the microorganisms begin to divide and produce extracellular polymeric substance (EPS), which enhances adhesion, while forming the matrix that embeds the cells; 'biofilm maturation', whereby 3D structures develop in which the EPS matrix provides a multifunctional and protective scaffold, enabling heterogeneous chemical and physical microenvironments to form where microorganisms coexist within polymicrobial and social interactions (competitive and synergistic); and finally 'dispersal', whereby cells leave the biofilm to re-enter the planktonic phase. Biofilms can be targeted at these various stages. a | The initial phase of biofilm formation can be disrupted -for example, by preventing the attachment of microorganisms by interrupting the interactions between the microorganism and the surface or by targeting cell-surfaceassociated adhesins (appendages, proteins and EPS). b | The inhibition of the early stages of biofilm development includes targeting the production of EPS and cellular division. c | Disruption of formed biofilms could be achieved by physical removal, the degradation of the EPS matrix, targeting the establishment of pathogenic microenvironments (low pH or hypoxia) and social interactions (in polymicrobial biofilms), as well as the elimination of dormant cells. d | Biofilm dispersion can be induced by EPS matrix remodelling or activation of dispersal mechanisms.
Adhesins
Bacterial or fungal surface-associated determinants that mediate adherence to living cells or attachment to abiotic surfaces and can promote virulence.
E. coli population by 3 logs 28, 30, 31 . A recent study has also attempted to address the low half-life and bioavailability of O-mannosides by generating C-mannosides, which have increased metabolic stability and in vivo efficacy. Prophylactic treatment with this compound reduced the E. coli burden by 2 logs, and treatment of chronic infection resulted in a 4-log reduction in a UTI mouse model 32 . Similarly, ring-fused 2-pyridones, which inhibit the biogenesis of curli and type I pili, reduced uropathogenic E. coli bladder colonization by more than 10-fold and the establishment of intracellular bacterial communities in an in vivo mouse UTI model 33 . Several other biomolecules that bind to EPS adhesins are discussed in detail elsewhere 34 .
Targeting the EPS chemical composition and structure. Exopolysaccharide-degrading enzymes, such as glucano hydrolases (dextranase and mutanase) and dispersin B, can disrupt the matrix of pathogenic oral biofilms, and glycoside hydrolases have been used to degrade a mixed-species Staphylococcus aureus and P. aeruginosa biofilm grown in a mouse model of chronic wounds [35] [36] [37] , although poor retention and enzymatic stability (for example, susceptibility to proteolysis) may compromise efficacy in vivo 36 . Nevertheless, a purified serine protease, Esp, from Staphylococcus epidermidis inhibited S. aureus biofilm formation and eradicated pre-existing biofilms in vitro, whereas susceptibility to the antimicrobial β-defensin 2 was enhanced, and S. aureus nasal colonization in humans was reduced 38 . Another approach used endolysins (bacteriophage-encoded peptidoglycan hydrolases), which enzymatically degraded the bacterial cell wall peptidoglycan 39 . Engineered peptidoglycan hydrolase constructs with distinct antimicrobial activities degraded multiple unique bonds in the peptidoglycan structure that are specific to S. aureus 40 and increased killing and biofilm removal in animal models. Fusion proteins derived from multiple bacteriophage-encoded endolysins, each with unique actions, all added simultaneously may also decrease the risk of resistance but show sufficient specificity to avoid targeting commensal strains. Glycoside hydrolases were recently shown to both disrupt pre-existing P. aeruginosa biofilms and potentiate neutrophil-mediated killing 41 . DNases have also shown efficacy in disrupting biofilms 42 . Consistent with the role of eDNA in the EPS matrix and in early biofilm development, DNase I is effective in disrupting early biofilms in vitro and in vivo 42, 43 . Notably, other biomolecules, including polysaccharides and various proteins that are associated with eDNA, contribute to biofilm structural integrity, which may explain the efficacy of DNase I in treating nascent biofilms. Few studies have used DNases to specifically target biofilms in vivo; however, it was shown to decrease Gardnerella vaginalis colonization on vaginal mucosal epithelial cells in a mouse model with statistical significance 44 . Therapeutic use of recombinant human DNase I (dornase alfa) degrades neutrophil and microorganism-derived DNA in the sputum of patients with cystic fibrosis, thus reducing sputum viscosity 45 . An intervention study with dornase alfa in patients with cystic fibrosis and early lung disease showed significantly improved lung function and a lower risk of exacerbation compared with placebo groups, with a potential decrease in the rate of lung function decline in children 46 . A clinical trial investigating the efficacy of dornase alfa for the treatment of chronic otitis media,
Box 1 | Common features of microbial biofilms
Chemical composition and physical properties Adherence. Microorganisms can adhere to almost all man-made materials (that is, plastics, metals, ceramics and hybrids) and biotic surfaces (for example, tooth enamel, bone, skin, airway, intestinal and vaginal mucosa, connective tissue and vascular endothelium), using both specific (bacterial adhesin-host receptor interactions) and non-specific (hydrophobic or electrostatic forces) adhesion mechanisms 154 .
Extracellular polymeric substance (EPS) matrix. Although the precise chemical and physical composition of the EPS (polysaccharides, proteins and nucleic acids) varies between species and growth conditions (that is, nutrient type and abundance, hydrodynamics, temperature and oxygen concentration), the EPS provides a scaffold for mechanical stability, and creates compartmentalized chemical and physical microenvironments that afford protection to the cells within a heterogeneous 3D structure.
Architecture. Although there is some variation in the structure of biofilms grown in vitro, there are a limited number of common forms (flat patches, mounds, mushrooms, towers, ripples and streamers) that are not generally species specific but are largely dependent on biofilm maturity and the production of certain EPS components and growth conditions. Biofilms observed in many clinical specimens tend to consist of aggregates of cells of varying sizes and mixed-species in polymicrobial systems 155 .
Viscoelasticity. A material property that enables biofilms to absorb and dissipate energy, rather than detach, when exposed to mechanical forces, such as hydrodynamic shear. The elastic component enables the biofilm to spring back into shape during intermittent perturbations, whereas the viscous component enables biofilms to flow similar to liquids when forces are sustained 5 .
Heterogeneity. Biofilms are heterogeneous (non-uniform) in distribution, 3D structure and physiology at various spatial scales. On the larger scale (millimetres to centimetres) they are generally not uniformly distributed on surfaces but occur in patches of cell clusters (also referred to as microcolonies or aggregates) in a range of sizes and shapes. Within the biofilm, heterogeneous microenvironments (10-100 μm) develop that modulate microbial activity, intercellular signalling and metabolic exchange, which lead to spatial organization of cellular and communal behaviours -important factors for tolerance and persistence.
Physiological and regulatory aspects
Developmental life cycle. Pseudomonas aeruginosa is a widely used model organism for studying the formation of microbial biofilms. Although many of the concepts identified in this organism, such as the mechanism of attachment, growth, maturation and dispersal, are widely conserved among other biofilm-forming pathogens, there may be fundamental differences. For example, many biofilm-forming species, such as staphylococci, unlike P. aeruginosa, are non-motile, many species have surface structures that are important for adhesion (capsule, pili or flagella) but many do not, and lastly not all species have known cell signalling systems.
Diffusible cell signals.
These signals co-ordinate population behaviour 156 , metabolic activity, biofilm formation and dispersal. Families of homoserine lactones are produced by many Gram-negative bacterial species, whereas Gram-positive organisms more commonly use autoinducing peptides (AIPs).
Altered microenvironment formation. The development of gradients in nutrients, pH and oxygen as a consequence of the metabolic activity of microorganisms that reside in a biofilm and diffusion-limited mass transport of molecules into and out of the EPS matrix alters the microenvironment in the biofilm.
Dormant or slow-growing subpopulations.
These include persisters and small-colony variants (SCVs), which are tolerant to antibiotics. In addition, nutrient depletion in the interior of the biofilm can result in a stationary-phase-like dormancy. 
Curli
A class of bacterial amyloid (aggregates of proteins that form insoluble fibres) produced by many members of the Enterobacteriaceae and a major component of the extracellular matrix, promoting surface adhesion, cell aggregation and biofilm formation.
Type I pili
Filamentous surface structures that have a FimH adhesin at the pilus tip, mediating adherence to host cells and uropathogenic Escherichia coli invasion of bladder epithelial cells.
Antimicrobial peptides
A subset of host defence peptides with antibiotic activity. Peptides such as LL-37 (cathelicidin) and human β-defensins are rapidly acting, small-molecule effectors that are part of the innate immune response of the host.
at the time of tympanostomy tube insertion to promote bacterial clearance from the middle ear combined with antibiotic drops, is under evaluation 47, 48 . Matrix-degrading enzymes can help disperse bacteria in biofilms for more effective killing when combined with antimicrobial agents. Targeting EPS can also disrupt the viscoelastic properties to further weaken biofilm cohesiveness and enhance antimicrobial efficacy, including host mediated antimicrobial responses. Recent studies have shown that glucano-hydrolases, glycoside hydrolases and DNases enhance antimicrobial delivery and potentiate killing by antibiotics or antimicrobial peptides when used in combination against pre-formed biofilms in vitro 49, 50 . Overall, EPS synthesis inhibitors or EPS-degrading enzymes, which lack intrinsic antibacterial activity, seem to be a promising adjunctive approach for biofilm control that could potentially enhance the killing efficacy of antimicrobial agents and promote biofilm removal when co-administered.
EPS-targeted antibodies and nucleic acid-binding proteins.
Vaccine approaches pose several challenges as a strategy to target biofilms, as vaccines are specific to a microorganism and clinical isolates from biofilm infections show considerable variability in genotype and/or the phenotypic expression of vaccine-targeted epitopes 51 . A more effective approach may be to use antibodies that target specific EPS components. Monoclonal anti bodies against P. aeruginosa-derived EPS identified epitopes that bound to the polysaccharide Psl, which is widely present in clinical isolates of P. aeruginosa 52 . Psl was shown to be a serotype-independent antibody-accessible antigen, and Psl-specific antibodies increased opsonophagocytic killing of P. aeruginosa, inhibited adherence to lung epithelial cells in vitro and showed prophylactic protection in several animal models of P. aeruginosa infection. In addition, vaccine-elicited antibodies to Enterococcus faecalis pilus tip (EbpA) abrogated bacterial binding to fibrinogen and biofilm formation in a mouse model of catheter-associated urinary tract infections (CAUTI) 53 . Notably, EbpA did not mediate the adhesion of E. faecalis directly to the catheter material but, rather, inhibited binding to fibrinogen deposited on the catheter surface. The EbpA antibody response prevented EbpAmediated fibrinogen-dependent bacterial aggregation and biofilm formation on catheters. This approach highlights why using a complex host-microorganism model can reveal additional targets. In another approach, a multivalent vaccine that targets both planktonic and biofilm-expressed polypeptides from S. aureus showed increased efficacy in combination with antibiotics compared with antibiotic treatment alone in a rabbit model of osteomyelitis 54 . Nonetheless, targeting broadly conserved components in EPS is desirable. The DNABII family of DNAbinding proteins has a key role in providing structural integrity to eDNA 55 . The high binding affinity of integration host factor (IHF) has specifically been used to target nucleoproteins in biofilms and has been widely tested in animal models. Antibodies against E. coli IHF are cross-reactive and bind to DNABII in several bacterial species, resulting in biofilm destabilization and the release of individual bacteria. When combined with antibiotic therapy, immunotherapy targeting DNABII has shown efficacy in vivo against biofilms in numerous types of bacteria, including oral bacteria 56 , uropathogenic E. coli 57 and P. aeruginosa in a mouse lung infection model 58 . This approach has also shown efficacy against methicillin-resistant S. aureus (MRSA) biofilms compared with antibiotic treatment alone in mouse models 59, 60 . In a combinatorial approach without using antibiotics, DNABII antibodies were combined with a vaccine strategy. A study with non-typeable Haemophilus influenzae (NTHi) in an animal model of otitis media used IHF and recombinant soluble type IV pili (rsPilA) co-administered with an adjuvant and delivered by transcutaneous immunization to achieve early NTHi eradication and prevent disease 61 . This approach also resulted in the disassembly of NTHi biofilms that were established before immunization, thus leading to resolution of existing disease.
Inducing biofilm dispersal
Biofilm dispersal has been shown to be a regulated process that involves the degradation of the EPS matrix, and the triggering of this response has provided research strategies designed to promote biofilm self-disassembly. These approaches, for the most part, assume that dispersed bacteria have returned to an active state similar to their planktonic phenotype, rendering them more susceptible to conventional antibiotics. Furthermore, liberated inactive cells will also have lost a degree of protection conferred by their association with the biofilm community and structural organization. Regardless of their dispersed state, it remains vitally important in
Box 2 | Lessons learned from cancer
Over 100 years ago, Paul Ehrlich, the German physician scientist, used the term 'magische Kugel' to describe an ideal hypothetical therapeutic agent that specifically targets and kills disease-causing cells 157 . In the context of cancer, the targets of such a magic bullet were the newly discovered receptors found on tumour cells. Another magic bullet was interferon , the cytokine that was discovered in 1957 (REF. 158 ). However, a magic bullet for cancer therapy remains elusive, in part, because over the past 40 years of intense molecular research, as stated by Harold Varmus, 14th Director of the National Cancer Institute, it has become clear that "cancer is not simply a single disease that affects many parts of the body. Rather, it is many different diseases with common themes that can cause different kinds of disorders in many of our organs" (REF. 159 ). In addition, individual tumours exhibit substantial chemical and clonal heterogeneity with distinct phenotypes that, combined with the ability of cancer cells to rapidly adapt to chemotherapeutics and their microenvironment, challenge both broad-spectrum and targeted therapies. In tumours, the structure and composition of the extracellular matrix are often altered, creating a favourable cellular niche for malignant transformation and cancer progression. Biofilms share similar common themes
, including the ability to create distinct microenvironments with unique chemical, physical, phylogenetic, genotypic and phenotypic heterogeneities. Early cancer therapy borrowed from approaches to treat acute bacterial and viral infections by targeting individual cells (with antibiotics and vaccination), with limited success. Our current understanding of biofilm biology is following a similar path to tumour biology. Rather than piled-up assemblages of clonal cells, microbial biofilms represent a dynamic self-constructed ecosystem within a matrix that contains highly heterogeneous and compartmentalized milieu, and more effective biofilm therapies will probably need to target the complete microenvironment, as well as the individual cells within 144 . Targeting the c-di-GMP pathway. The intracellular secondary messenger nucleotide c-di-GMP has a key role in the biofilm life cycle of both Gram-positive and Gramnegative bacteria, whereby increased levels promote biofilm formation and reduced levels promote disassembly 62 . The enzymes that govern c-di-GMP levels, diguanylate cyclases (synthesis) and phosphodiesterases (breakdown), have GGDEF, EAL and HD-GYP domains that are found in numerous bacterial phyla. Therefore, this signalling pathway provides an attractive strategy to target multiple species, although the complexity of c-di-GMP regulation makes it challenging to control 63 . However, few studies that show biofilm dispersal have used relevant cell models in vitro or in vivo animal models. One study used a P. aeruginosa construct that contains an exogenous E. coli phosphodiesterase. When expression was induced in vivo it resulted in reduced c-di-GMP and the dispersal of biofilms on silicone implants in a mouse foreign body infection model 64 . Although, in principle, this study supports the potential use of such phosphodiesterases as a strategy to modulate c-di-GMP and target biofilms, the authors noted limitations of their findings, including an increased bacterial burden in the spleen. c-di-GMP is also a potent stimulator of host immunity through type 1 interferon responses, and therefore it may be difficult to attribute effects on biofilms specifically in vivo 65 . A well-characterized approach to modulate c-di-GMP levels is though nitric oxide (NO). NO was first shown to regulate c-di-GMP levels and mediate P. aeruginosa biofilm dispersal 66 at low concentrations, and these results have since been reproduced in several other bacterial species 67 . However, the use of gaseous NO or spontaneous NO donors presents clinical challenges, owing to potential cytotoxicity from systemic exposure, lack of specificity in targeting biofilm infections and cost. In addition, as NO is labile, the optimal concentration to disperse biofilms is difficult to measure; however, NO microelectrodes are highly sensitive and offer excellent spatial and temporal resolution in tissues or body fluids. In a recent proof-of-concept preclinical study, low-dose gaseous NO in the picomolar-to-nanomolar range was shown to reduce the size of the P. aeruginosa biofilm aggregate in sputum as a primary clinical outcome in a small number of patients with cystic fibrosis 68 . Patients did not exhibit adverse effects to NO therapy. Although the biofilm aggregate size was significantly decreased, NO did not reduce colony-forming units as seen in another study 69 , perhaps because patients continued to receive antibiotic therapy throughout the study period. However, a phase I clinical trial is ongoing to study the efficacy and safety of NO in patients with cystic fibrosis 70 .
To address the cost of administering gaseous NO and potential systemic cytotoxicity issues, cephalosporin-3ʹ-diazeniumdiolates (C3Ds), composed of a stabilized diazeniumdiolate NO donor attached to the 3ʹ-position of cephalosporin, have recently been developed to selectively deliver NO to bacterial biofilms 71 . These prodrug candidates are designed to specifically release NO following cleavage of the cephalosporin β-lactam ring by bacterial β-lactamases and have been shown to be effective in dispersing in vitro P. aeruginosa biofilms 71 . NTHi biofilms grown on primary ciliated epithelia also showed enhanced sensitivity to the antibiotic azithromycin, reducing viability by 2 logs when a specific components, and the underlying mechanisms that are responsible for the production and secretion of EPS components, represent attractive targets for the development of biofilm-targeting strategies, some of which have potential efficacy across microbial species. One approach includes the degradation of the EPS. Treatments have been developed that directly target the eDNA (DNases), exopolysaccharides (dispersin B, glycoside hydrolases and monoclonal antibody vaccines) and protein (DNABII family antibodies) components of the matrix. EPS adhesin-binding antibodies or inhibitors, and phage-encoded peptidoglycan hydrolases have been developed to target bacterial adhesion and biofilm initiation. Inhibitors of EPS synthesis and the secretion systems have also shown promise to disrupt biofilm accumulation. Endogenous pathways that induce biofilm dispersal can also be targeted, including the regulation of cyclic-di-GMP and cyclic-di-AMP levels using exogenous nitric oxide and inhibitors, or targeting quorum sensing using various inducing peptides and messenger molecules. Importantly, all of these treatment strategies, alone or in combination, can lead to the inhibition of biofilm formation, disruption of biofilm integrity and/or promotion of the release of individual bacterial cells that are more susceptible to conventional antibiotic treatment, thereby enhancing clinical efficacy.
Nitric oxide (NO).
A ubiquitous signalling molecule found in both prokaryotic and eukaryotic systems. NO is toxic in the millimolar range, but in the picomolar and nanomolar range it can be used to form reactive oxidative and nitrosative species that interact with proteins, DNA and metabolic enzymes. As NO is labile, the optimal concentration to disperse biofilms is difficult to measure; however, NO microelectrodes are highly sensitive and may provide excellent spatial and temporal resolution in tissues or body fluids.
C3D -PYRRO-C3D -was used as an adjuvant; this response is possibly attributable to dispersal and modu lation of metabolic activity 72 . This effect was also demonstrated in a study that used primary epithelial cells from patients with primary ciliary dyskinesia (PCD), which is a disease that compromises mucociliary clearance. Airway cells from patients with PCD showed increased susceptibility to NTHi biofilm formation compared with epithelial cells from healthy individuals, and PYRRO-C3D in combination with antibiotics significantly decreased NTHi viability by 2 logs compared with antibiotic treatment alone 73 . The treatment of infected healthy airway cells and infected airway cells from patients with PCD had no effect on transepithelial electrical resistance, which suggests that epithelial barrier function was unaffected. Although this alone is not a sufficient assessment of toxicity, the targeted release of low NO concentrations (48-90 nM) should improve the safety of patients.
NO donor instability is also an issue that is being addressed by developing nitroxides (sterically hindered NO analogues) that exert biological responses through NO-mimetic properties 74 . These molecules (such as carboxy-TEMPO, CTMIO and DCTEIO) eli cited biofilm dispersal in P. aeruginosa and E. coli similar to NO, with carboxy-TEMPO also reducing tolerance to ciprofloxacin 74, 75 . However, treatment with carboxy-TEMPO failed to disperse MRSA biofilms, which indicates that this approach may be restricted to biofilms formed by certain species. This highlights an ongoing concern for polymicrobial biofilms infections. Other drugs that are currently under development include ciprofloxacin-nitroxide conjugates, which, similar to C3Ds, combine antibiotic activity with a donor compound 76 , and fimbrolide-NO donor hybrids, which simultaneously target quorum sensing and NO pathways 77 .
Targeting quorum sensing. The role of quorum sensing systems in biofilm development and dispersal provides another intensely studied strategy for the development of novel therapeutics. Quorum sensing requires the binding of a signalling molecule to a corresponding transcriptional regulator, which activates the downstream transcription of select targets. As the production of many virulence determinants in pathogenic bacteria requires cell-cell communication, quorum sensing inhibitors (QSIs) that target the AHL-based quorum sensing system in Gram-negative bacteria or the quorum sensing systems in Gram-positive bacteria have been extensively evaluated for efficacy on clinically relevant bacterial biofilms using in vitro and in vivo models. For example, the quorum sensing autoinducer, autoinducer 2 (AI-2), functions as a chemorepellent in Helicobacter pylori by regulating the proportion and spatial organization of biofilm cells 78 . Treatment of in vitro biofilms with exo genous AI-2 resulted in both a reduction in the proportion of adherent cells and dispersal 78 . Autoinducing peptide type I (AIP-I) also triggered dispersal in MRSA biofilms on titanium disks, rendering detached MRSA more susceptible to treatment with rifampin and levofloxacin 79 . In addition, the use of an RNAIII-inhibiting peptide (RIP) resulted in a 7-log reduction in MRSA compared with 5-log reductions observed with RIP-soaked Allevyn or teicoplanin treatments alone in a mouse wound model 80 . A recent study used a high-throughput screen to identify a benzamidebenzimidazole derivative, termed M64, that interferes with the Pseudomonas quinolone signal (PQS) quorum sensing system, which regulates biofilm formation and the production of virulence factors in P. aeruginosa 81 . Interestingly, M64 reduced both the virulence and persistence of the P. aeruginosa strain PA14 in mouse models of burn and lung infections when used alone, and it reduced the bacterial load further when used in combination with ciprofloxacin. M64 also did not exhibit cytotoxicity in mouse macrophages and was shown to decrease the number of persister cells in the population.
Although the increased efficacy of antibiotic treatment with QSI in vivo is promising, reduced bacterial loads often depend on the strain and biofilm model 82 . Furthermore, quorum sensing molecules can be washed away during biofilm initiation, whereas the EPS matrix can bind to and sequester quorum sensing molecules, and the effects may be limited to highly localized areas within the biofilm structure 1 . Therefore, inhibitors need access and specific targeting to the site of active quorum sensing signalling. These factors in addition to the complexity in cell signalling networks, make it a challenging therapeutic approach albeit such inhibitors can be used in combination with other strategies.
Metabolic interference
The potential of exogenous amino acids in the treatment of biofilms has attracted considerable interest, and specific amino acids have been shown to affect both biofilm metabolism and development. l-arginine (l-Arg) functions as a substrate for alkali production by arginolytic bacteria (for example, Streptococcus gordonii), which has been shown to neutralize acids and modulate pH homeostasis within oral biofilms clinically 83 . Treatment of polymicrobial biofilms comprising S. mutans, S. gordonii and Actinomyces naeslundii with l-Arg suppressed the growth of S. mutans and resulted in a substantial reduction in insoluble EPS and altered biofilm architecture 84 . In addition to pH modulatory effects 83 , l-Arg also repressed genes that are involved in the production of insoluble EPS and bacteriocin in S. mutans, while increasing hydrogen peroxide (used against S. mutans) production by S. gordonii 84 . l-Arg reduced biomass and altered EPS architecture in S. gordonii biofilms 85 , and also destabilized multispecies oral biofilms, thus redu cing viability and increasing susceptibility to cetylpyridinium chloride 86 . An alternative amino acid, l-methionine (l-Met), was also identified as a promising adjuvant for treating P. aeruginosa biofilms, triggering disassembly and increasing sensitivity towards ciprofloxacin in a mouse model of chronic pneumonia and enhancing the survival of infected mice 87 . This activity was attributed to the upregulation of four different DNase genes and the subsequent degradation of eDNA in the EPS matrix, although the exact pathways that regulate this response were not determined. Interestingly, l-Met seems to have 
Biguanides
Class of organic compounds (C2H7N5) used as oral antihyperglycaemic drugs. Derivatives of this compound with bactericidal activity are commonly used as antiseptic and disinfecting agents such as chlorhexidine.
been chosen for this study following screening of a selection of d-amino acids and l-amino acids for their activity against P. aeruginosa biofilms. Given the diversity in amino acid use between bacterial species, it is unlikely that a single amino acid would have a universal function; however, their importance, and that of bacterial metabo lism in general, should not be underestimated in the development of future treatment strategies.
Another approach is based on evidence that iron metabolism is important for the formation of biofilms in several pathogens [88] [89] [90] [91] . Iron acquisition is crucial for patho gens to establish infection, and epithelial cells that contain the cystic fibrosis transmembrane conductance regulator (CFTR) ΔF508 mutation showed that increased biofilm formation by P. aeruginosa was linked to increased availability of iron 92 . Host defences normally actively sequester iron to limit the growth of infecting bacteria, as iron is an essential nutrient. However, P. aeruginosa has redundant iron receptor and uptake systems, such as siderophores, and other iron-chelating molecules. Gallium, which is chemically similar to iron, is taken up by bacteria but does not replace the functionality of iron, thus inhibiting the iron-dependent pathways required for cell growth and biofilm formation. This 'Trojan horse' strategy interfered with the growth of P. aeruginosa and iron metabolism, killed planktonic bacteria in an acute mouse pneumonia model and reduced bacterial counts in established biofilms by 3 logs in a chronic biofilm lung infection model 93 . Gallium was administered through inhalation and, importantly, uptake was independent of the P. aeruginosa siderophore pyoverdin in vitro. However, in vivo it was unclear whether gallium may have anti-inflammatory effects other than directly inhibiting biofilm formation. Nonetheless, using iron chelators adjunctively with tobramycin reduced P. aeruginosa in a co-culture model of human bronchial epithelial cells from a patient with cystic fibrosis that carried the CFTR ΔF508 mutation, resulting in a 7-log reduction in viable bacteria and also prevented biofilm formation on these cells 94 . More recently, the oxidation state of iron was shown to be important 95 ; this study examined mucus from the airways of patients with cystic fibrosis and found that ferrous iron was the primary form of bioavailable iron, which also correlated with the severity of cystic fibrosis lung disease, whereas ferric iron did not, thus highlighting the importance of directly investigating the phenotypic state of bacteria in situ in human infections and its potential translational relevance in informing new therapeutic approaches.
Targeting dormant cells in biofilms
Targeting pathways to induce processes such as dispersal requires that cells are metabolically active. However, evidence also shows that persisters residing within biofilms have a key role for drug tolerance
. Therefore, it is attractive to consider antimicrobial approaches that physically or chemically disrupt cells rather than interfering with cellular processes. Non-discriminating oxidizing agents, such as hypochlorite and hydrogen peroxide, have been used as irrigants in wound 96 and endodontic debridement 97 . However, studies reveal that even strong oxidizers, such as sodium hypochlorite, fail to eradicate biofilms 98 , probably because long-term exposure is not possible owing to cytotoxicity concerns. Broadspectrum cationic biguanides, such as chlorhexi dine or quaternary ammonium, adhere to cell walls and disrupt cell membranes. However, penetration was limited over the expected timescales used in ex vivo dental biofilms 99 , with longer term exposure increasing cytotoxicity, thus making this approach clinically impractical.
Other exploratory avenues include antibiotics that are used for the treatment of infections caused by slow-growing bacteria. Rifampin, which is used to treat staphylococcal orthopaedic implant infections, raises concern about the development of rifampin resistance. However, used in combination with other antibiotics, rifampin and fosfomycin enhanced efficacy in treating foreign body MRSA biofilm infections in vivo 100 . Likewise, disrupting a cellular target in dormant cells can kill persisters. The acyldepsipeptide antibiotic (ADEP4) can activate the ClpP protease in dormant persister cells in Gram-positive bacteria, so the cells effectively 'digest' themselves. Although it is an elegant concept to endogenously activate cytoplasmic enzymes for proteolytic degradation in biofilms, it should be noted that ClpP is not an essential enzyme, and ClpP-null mutants are not affected by ADEP4. To address this, treatment with both ADEP4 and rifampin showed good efficacy in a mouse chronic biofilm deep abscess-like infection model 101 using various S. aureus species. However, this study illustrates that careful consideration needs to be given to antibiotic pairings, particularly in this case, as rifampin resistance occurs at high frequency and so it is usually combined with other active antimicrobials. In the case of ClpP-null mutants, ADEP4 would be ineffective and rifampin would in effect be acting as a monotherapy.
Box 3 | Persistence, resistance and tolerance
The terms persistence, resistance and tolerance are often used interchangeably when used to describe the inability of antibiotics (and antimicrobial agents) to inhibit or kill bacteria within a biofilm to the same extent as planktonic cultures 160 . 'Resistance' usually has an underlying heritable genetic basis that might be acquired through point mutation or horizontal gene transfer, and is defined through standardized minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays. 'Tolerance' is less-well defined and is arguably more appropriately used when antibioticsusceptible strains (by MIC and MBC) require much higher concentrations to obtain similar log reductions when growing in the biofilm phenotype. Importantly, tolerance can be lost when biofilms are dispersed into single cells, thus dispersal strategies are normally considered as adjuvants for antimicrobial therapy. However, dispersed planktonic aggregates of cells may still retain tolerance. 'Persistence' (and persistent biofilm) is a term that is loosely used to describe a clinically protracted unabated biofilm infection despite treatment. However, persistence in this sense should not be confused with 'persisters' (REF. 161) or subpopulations of cells that have a distinct dormant phenotype that affords them protection against antibiotics, which kill the metabolically active population. Persister cells can occur in both planktonic and biofilm cultures, but the stressful conditions, physical stability and protection from host phagocytes afforded by the biofilm microenvironment seem to contribute to harbouring microbial populations, which grow and repopulate once the antibiotic stress is removed. It is thought that these populations are tolerant to conventional antibiotics because there are no active cellular processes to interrupt. These subpopulations can form spontaneously or can be induced from environmental stresses in the biofilm microenvironment 162 (see REF 161 for a review).
Nanoparticles
Structures with a size range between 1-1000 nm. They can be classified as organic or inorganic and can exhibit antibacterial properties or can be used as drug delivery systems.
Surfactants
Compounds that lower the surface tension between liquids and solids. Surfactants are used as cleaning detergents, and some biofilm bacteria produce their own surfactants in order to disperse from a surface.
Topographic surface patterns
Patterns, including protruding squares, cone-shapes, wrinkle and ridge-like patterning or nanopores, that disrupt bacterial adhesion.
Biofouling
The unwanted accumulation of microorganisms and macroorganisms on surfaces. Microbial biofilms are often considered 'biofouling', particularly in the context of manmade industrial surfaces.
Antimicrobial peptides (AMP) represent another approach in treating biofilms independent of the presence of microbial activity. An important advantage of AMPs is that they are widely conserved and are therefore attractive as broad-acting antimicrobial agents that may be useful against both bacterial and fungal biofilms 102, 103 . Conversely, species-specific targeting is also possible with synthetic AMPs that consist of dual functionally independent moieties (a broad-spectrum AMP with a killing moiety and a species-specific binding peptide with target specificity). This approach may remove specific pathogens, such as S. mutans, from oral multi species biofilm communities to promote a 'healthy-like micro biome' , as was shown in vitro 104 . Another advantage is that the pore-forming activity of an AMP targets respiring cells as well as persister and dormant populations, which might reduce the potential for bacteria to develop resistance to AMPs. Therefore, AMPs have potential as therapeutics to target biofilms. Synthetic peptides that modify specific AMP sequences were designed that showed both inhibitory activity and, when used together with anti biotics, enhanced the killing of P. aeruginosa biofilms in invertebrate infection models 105 . Specific peptides also triggered the degradation of guanosine pentaphosphate (ppGpp), which prevented the accumulation of this secondary messenger and abrogating biofilm formation of several Gram-positive and Gram-negative pathogens 103 . However, more preclinical efficacy studies are required, as AMPs can bind to EPS matrix components and to other host molecules, which decreases their effectiveness, and microbial proteases may further diminish AMP potency 106 . In addition, the high cost of AMP synthesis is a barrier for clinical development and commercialization, although using chloroplast-based technology for large-scale production in automated greenhouses may mitigate costs 50 . Nevertheless, AMPs can be immobilized onto solid surfaces to enhance efficacy or specificity. This was particularly effective as a polymer-based approach on catheters, as AMP coatings greatly reduced P. aeruginosa adhesion and infection over 7 days in a mouse UTI model 107 . Furthermore, structurally nanoengineered AMP polymers exhibited potent killing activity against several Gram-negative, colistin-resistant and multidrug-resistant pathogens, and they exhibited low toxi city and efficacy in an animal model of Acinetobacter baumannii infection 108 . The recent completion of two phase II clinical studies of brilacidin (a membrane-acting AMP mimetic) as an intravenous agent for skin infections demonstrates the feasibility of AMPs for systemic therapeutics 109 . AMPs can also enhance conventional antimicrobial activity, and the combination with strategies that target the EPS matrix may further increase both the access and permeabilizing properties of AMPs once in the biofilm 50, 103 . Although targeting tolerant cells using AMPs is a promising approach, reaching the target cells that are embedded within a biofilm either topically or systemically, and for the compound to be active across a spatially and chemically heterogeneous microenvironment, remain important challenges in vivo. The stability and durability of AMP coatings within the body is also an issue that needs to be further addressed, particularly at places that wear might be expected owing to shear caused by moving tissues and fluids as well as proteolytic degradation.
The promise of new technologies While our understanding of biofilm microenvironments is evolving, technological advances are providing unprecedented avenues to develop multi-targeted therapeutic approaches that prevent and disrupt biofilms or enhance drug efficacy (FIG. 3) . Nano-and chemical engineering approaches provide unparalleled flexibility to control the composition, size, shape, surface area and surface chemistry, and functionality of nanostructures that can be used to develop a new generation of modified materials or to coat existing solid surfaces to prevent the formation of biofilms. Functionalized nanoparticles, including stimulitriggered activation, can be designed to enhance penetration and selectively target or release drugs locally after bacterial attachment or within biofilms. In this Review, we focus on overall concepts and provide insights into their clinical potential based on recent studies using in vivo models. We have provided a full list of current and prospective technologies and additional references in Supplementary information S1 (table) .
Surface modifications. Surface-tethering or the incorporation of an antibiotic or biocide within a 'reservoir' coating has long been studied as a possible approach to inhibit bacterial adhesion and biofilm formation 110 . However, sustaining efficacy and therefore justifying their progression to wide-scale use into the clinic has been challenging. The amount of biocide required to achieve efficacy, as well as its chemical composition, may be limited by potential deleterious effects; this was exemplified by silver nanoparticles, which were shown to be toxic in a rat infection model 111 . In addition, antimicrobial reservoir coatings are subject to progressive decreases in efficacy as the active agent is depleted and thus have a limited lifetime of activity. Furthermore, nonspecific absorption of exogenous surfactants and proteins may mask the engineered surface and coatings or hinder the release of antimicrobial agents.
Advances in material and surface engineering have led to the development of well-defined topographic surface patterns that can control biofilm formation without including antimicrobial agents 112 . A commercially developed ordered topography is the Sharklet surface. Inspired by shark skin and its inherent antibiofouling properties, microscale ribs of various lengths are combined into a repeating diamond micropattern, creating a textured surface that prevents macro and micro biofouling 113 , as well as bacterial colonization and biofilm formation when incorporated into the surfaces of medical devices 114 . Surface modifications are mostly focused on nonspecific protein repulsion and the inhib ition of bacterial colonization. This can be challenging owing to the structural and physiochemical diversity of the numerous proteins in biological fluids that surround a surface in a biomedical setting 115 . Hydrophilic polymer brushes 
Targeting persisters

Super-hydrophobic surfaces
Surfaces that maintain air at the solid-liquid interface when hydrated. This leads to improved functionality through water repellency or reduced drag.
or tethered polymers, such as polyethylene glycol (PEG), are widely used in the prevention of medical device fouling 116 . Although early bacterial adhesion is attenuated, probably due to the inhibition of an initial protein priming layer, the multifaceted nature of bacterial colonization (often involving non-proteinaceous adhesins) can lead to eventual biofilm formation 117 . Further studies with super-hydrophilic (super-wet) or super-hydrophobic surfaces have decreased protein deposition and bacterial attachment of clinically relevant surfaces 115, 118 . The incorporation of these materials into medical devices shows promising but variable results. Although greater sustainability of super-hydrophobic surfaces following mechanical abrasion has recently been demonstrated 119 , the anti-biofilm effects of these surfaces are often transient or subject to species bias 120 . However, short-to-medium-term biofilm suppression may be sufficient to permit effective immune and prophylactic responses and tissue integration of a foreign body.
The development of functionalized medical implant surfaces with a vast range of antimicrobial and antibiofilm properties has been intensely studied, particularly with respect to titanium implants. To use these surfaces in biomedical applications, modern surface design has been largely driven by top-down methods, such as lithography, imprinting and others 121 , to produce a vast range of antibacterial coatings, including, but not limited to, silver, copper, titanium dioxide and a | The material and surface properties of medical devices, such as surface charge, hydrophobicity, roughness, topography and chemistry, among others, can be modified to prevent bacterial attachment and thus attenuate or block biofilm formation. In addition, 'smart' or stimuli-triggered responsive surfaces can be constructed that elicit their effect only in response to physical contact with cell wall-associated or membrane-associated adhesins or bacterial chemical cues (such as secreted extracellular polymeric substance (EPS) and metabolites) or external triggers (such as photoactivation or pH). b | Advances in nanoparticle synthesis have led to the development of diverse approaches to combat biofilms. Inorganic metallic nanoparticles (such as silver, copper, iron oxide and gold) and organic nanoparticles (such as liposomes, aptamers and polymers) have been increasingly evaluated to improve their anti-biofilm efficacy, as well as their biocompatibility to reduce toxic effects on the host. Nanoparticles can be used to form nanocoatings, be incorporated into materials as composites or fillings, or combined with conventional antimicrobials and other approaches designed to physically disrupt or remove the biofilm. Furthermore, antimicrobial peptides (AMPs) and aptamers also have specific biofilm-targeting properties that can be used to enhance the specificity and efficacy of nanoparticles (hybrid nanoparticles). c | New technologies for physical biofilm removal, including mechanical, energy-based and light-based disruption, may further improve biofilm intervention strategies. Given the multifaceted nature of biofilm formation and the complex microbial interactions with the surrounding physical and chemical environment, a combination of these approaches may be required to successfully combat biofilm-mediated disease.
Smart surfaces
Surfaces that elicit their effect only upon contact with certain physiological, physical or physiochemical cues to provide targeted application, thus increasing therapeutic precision and reducing the risk of cytotoxity.
chitosan. Furthermore, emerging bottom-up approaches using nanomaterials as 'building blocks' (REF. 122 ) and surface attachment and immobilization of biomol ecules, including antimicrobial peptides or proteins and polysaccharides 123, 124 , have also resulted in the development of antibacterial surface coatings. Moreover, the unexpected discovery that certain bacterial poly saccharides can inhibit biofilm formation 124 , has led to the development of strategies to counter biofilm formation. Hyaluronic acid (which is one of the most studied polysaccharides) reduced the adhesion of S. aureus to hyaluronic acid-coated titanium surfaces 125 and poly(methyl methacrylate) intraocular lenses 126 . Bottom-up surface assemblies can also be combined with top-down surface processing 127 to generate nanocoatings with biofilm-targeting properties and biocompatibility 128 . Recent in vivo studies demonstrated the feasibility and efficacy of tunable multi-layer nanocoatings that released different combinations of anti biotics 129 or the sequential delivery of gentamicin and an osteoinductive growth factor 130 in a time-staggered manner for the prevention of biofilm-associated infection and bone tissue repair around implants. Both studies demonstrated the ability to prevent biofilm formation on the device surface, relative to uncoated controls, with the nanocoatings able to clear infiltrating bacteria and prevent colonization of the implant while promoting bone formation and osseointegration. Importantly, biocompatibility, as well as long-term host retention and release kinetics, were also demonstrated, thus providing promise for their more widespread application in orthopaedics.
Efforts to engineer surfaces with even more control over the specificity and sensitivity of their antibacterial or anti-biofilm capabilities have led to so-called smart surfaces, which are also known as stimuli-responsive or triggered biofilm-targeting surfaces. Triggers, including pH, temperature, salt concentration, metabolites, electrical currents and photoactivation, inducing topographical and chemical changes in the surface area as well as generating heat or induce drug release to kill or repel bacterial attachment (Supplementary information S1 (table)). The design principles for controlling bacterial adhesion or biofilm removal mechanisms that may be triggered on demand are intriguing. However, the effectiveness of these approaches has been evaluated largely in vitro. Consequently, as with all surface modifications, whether functionality will remain in vivo following the binding of endogenous host proteins in saliva, blood, synovial fluid and urine is unclear. Another consideration is that bacteria that associate with the surface may be killed and remain attached, thus masking the underlying technology and even providing a nutrient source for other bacteria. Therefore, it is important to not only have a killing effect but also a 'self-cleaning' mechanism, possibly facilitated by mechanical shear of surrounding body fluids or tissues. Furthermore, challenges to enhance mechanochemical stability and overcome coating deterioration and dissolution, and non-adverse host reactions to the coating itself will need to be addressed in future studies to facilitate clinical application [131] [132] [133] . Nanoparticles. Nanoparticles are versatile and bioactive and they are becoming increasingly popular as a biofilm-targeting approach. Nanoparticles with intrinsic antimicrobial activity, primarily inorganic materials such as silver, can act as biofilm-targeting agents or as nanocoatings (as described above). Owing to their flexible chemical structures, they can also function as drug delivery vehicles (nanocarriers), with organic nanoparticles accounting for over two-thirds of the systems approved for use in humans 134 . Furthermore, both inorganic and organic nanoparticles can be combined or modified by adding molecules (hybrid nanoparticles) to enhance their biological properties or provide multifunctionality. As excellent in-depth reviews on the principles and current applications of nanoparticles, particularly silver, are available 13, 135 , we focus on clinically used liposomal nanoparticles for drug delivery and emerging technologies, including stimuli-triggered activation, that have shown efficacy in vivo.
Liposomes are physiologically compatible vesicles that are composed of one or more phospholipid bilayers, and they represent one of the most widely developed organic nanoparticles for drug delivery. They are able to penetrate the biofilm well, are biocompatible and show efficacy against biofilms of a wide range of bacterial species for a diverse number of antibiotics 136, 137 . These nanocarriers can protect the antimicrobial agent from deleterious interactions with the matrix, or enzymatic inactivation and degradation at the infection site by other bacterial and host components. The lipid structure can also fuse with the bacterial outer membrane, releasing the drug directly into the cell, thereby potentially maximizing therapeutic effects while reducing host cytotoxicity 137 . Furthermore, liposomes can carry more than one drug by co-encapsulation and can also be functionalized by linking biomolecules (for example, peptides and pH-responsive polymers) on the nano particle surface to increase targeting specificity and triggered release. However, importantly, some studies have reported a reduced efficacy of liposomal-encapsulated antimicrobials dependent on the environment in which the biofilm resides; for example, host-derived and microorganism-derived substances, such as mucus and alginate, could inhibit bacterialiposome interactions 138 . Nevertheless, several formulations are currently in preclinical studies and clinical trials, and some are commercially available 139 . For example, liposomal ciprofloxacin and amikacin have shown promise in the management of chronic lung infection in cystic fibrosis 140, 141 . The potential of liposomes to function as delivery agents for other antimicrobials, such as NO, has demonstrated significantly reduced S. aureus biofilm mass compared with controls in a sheep model of chronic rhinosinusitis 142 . Although this study did not note any negative clinical symptoms, a transient increase in heart rate and decrease in mean arterial pressure were observed in the animals, which requires further investigation before this strategy can advance into human trials.
Nanoparticles with multifunctionality or on-demand activation following specific stimuli similar to smart surfaces represent the most widely developed class of nanoparticles currently under development (Supplementary 143 . Daily topical treatments effectively reduced the onset and severity of dental caries (tooth decay), preventing cavitation altogether in a rodent model of the disease. The pH-dependent functionality prevents catalytic reaction at physiological pH and unmitigated free-radical production, thus improving biocompatibility.
Stimuli-triggered mechanisms by nanoparticles can also enhance the selectivity of drug activation or delivery to cells within a biofilm, protecting host tissues and the commensal microbiota while targeting infective agents within pathological microniches [144] [145] [146] . Delivery of the antibacterial agent farnesol by acidic pH-triggered polymeric nanoparticles enhanced its biofilm-targeting activity fourfold (compared with farnesol alone); thus, the delivery system markedly improved the drug efficacy against an oral biofilm infection in vivo, following topical treatment 146 . These water-soluble polymeric nanocarriers can encapsulate hydrophobic and apolar drugs into aqueous solution, which is a crucial issue in product development. Similarly, nanoparticles that are conjugated with a pH-responsive element 145 or pH-sensitive surface charge switching 147 were developed to increase biofilm penetration and selective bacterial binding for targeted delivery and antibacterial activity in acidic conditions.
Another exciting area of development is in increasing the specificity of the nanoparticles by selectively targeting biofilm matrix constituents or through the introduction of bacteria-specific ligands, to improve both efficacy and biocompatibility. Nanoparticles functionalized with biofilm EPS matrix-digesting enzymes (DNase) and loaded with ciprofloxacin eradicated established P. aeruginosa biofilms without cytotoxicity against macrophages 49 . Likewise, tobramycin alginate-chitosan nanoparticles functionalized by conjugation to dornase alfa demonstrated better biofilm penetration and DNA degradation in sputum from patients with cystic fibrosis and increased protection against bacteria in an invertebrate infection model 148 . Furthermore, nanoparticles that were designed to release and activate NO in situ had antifungal and antibacterial effects, inhibited biofilm formation and promoted the degradation of the EPS matrix in vitro and in vivo 149, 150 . Recently, reports showed that linking antimicrobial peptides 102 or aptamers 151 to nanoparticle surfaces enhanced their killing efficacy, specificity or functionality. Overall, nanoparticles provide a promising therapeutic platform for the development of new effective biofilm-targeting approaches. However, although the development of novel nanoparticles has continued apace, there is a continually widening gap between the number of new formulations under laboratory investigation and those in clinical use. Further advances in this field should focus on enhancing in vivo efficacy (compared with current treatment modalities) and biocompatibility, and on understanding the potential toxicity and the metabolism of nanoparticles in the body. Affordable large-scale manufacturing would also be required for product development to the healthcare market. Nevertheless, the availability of previously FDAapproved nanoparticles demonstrates their potential for more widespread future clinical use.
Future directions
The initiation of a biofilm involves complex and dynamic interactions between the surface, the microorganism and the EPS. Following the establishment of a biofilm, the adhesive strength and viscoelastic properties make the removal of a biofilm from surfaces difficult, and resi dent microorganisms become tolerant to antimicrobials. Although tolerance is a common feature of biofilms, the mechanisms that underlie tolerance as a microbial survival strategy are multifaceted. Likewise, a reciprocal multifaceted approach to control The physical and biological complexity of biofilms and tolerance to antimicrobials render them less susceptible to conventional therapeutic approaches. Biofilm targets include microbial cells (often polymicrobial communities) and the extracellular polymeric substance (EPS) matrix, and therapeutics can be delivered from the overlying surrounding biological fluid as well as the surfaces of the medical devices themselves. We envision exogenous approaches (such as adhesion-targeting materials and coatings, and adhesin-blocking agents) to complement or synergize with endogenous activation (enhancing host immunity effectors) to prevent microbial attachment to host or abiotic surfaces in patients. Likewise, a combination of approaches that degrade the protective matrix, activate dispersal, and target the resident pathogens, persisters and dispersed cells without affecting commensals may be required to eliminate existing biofilms. Long-term effects of modified surfaces in the presence of biological fluids, as well as enhanced drug penetration properties and a decrease in toxicity or allergic reactions, are required for in vivo efficacy. These, combined with clinically relevant treatment regimen (either topical or systemic) and long-term effect assessment, should help successfully translate the hypothetical concepts into the clinic. The grey arrows indicate that biofilm bacteria and EPS can move or interact between the surface and fluid phases.
biofilms, in our opinion, is far more likely to achieve clinical success than a futile search for a magic bullet FIG. 4) . Understanding the complexity of biofilm biology highlights the role of complementary strategies that target both the microorganisms and the surrounding EPS matrix to either prevent the initiation of biofilm formation or to disrupt existing biofilms. The challenge of using antimicrobials alone, which may kill micro organisms but leave behind biodegradable substrates for microbial reutilization, must be addressed. Therefore, eliminating existing biofilms may require the simultaneous degradation of the protective EPS matrix and targeting and killing both resident microorganisms and dispersed cells. The complexity of polymicrobial interactions (synergistic, cooperative or antagonistic), spatial organization and community behaviour with host immune effectors further reinforces the need of a combinatorial therapy. Rapid advances in drug discovery methods should accelerate the identification of EPS inhibitors, inducers of biofilm dispersal and agents that target dormant cells, as well as therapies that enhance the host innate immune response 152, 153 . However, further validation of proof-of-concept studies using clinically relevant animal models, as well as clinical trials, are required for rigorous evaluation. Bacterial co-cultures with primary human cells to evaluate host-microbial response can be valuable to investigate; for example, the role of genetic mutations such as those found in patients with cystic fibrosis or PCD on the establishment and treatment of biofilms in patients suffering from these diseases. Opportunities to create physicochemical and biological structures, including organ-on-chip, within microfluidic devices or using 3D printed tissues and organoids may also help assess treatment efficacy by mimicking in vivo-like environments.
Furthermore, new technologies, including 'smartrelease' or 'on-demand activation' of bioactive agents by bacterial and external triggers (for example, EPS, metabo lites, pH or photoactivation), have enhanced selectivity and controlled in situ drug delivery.
However, most of the studies were conducted in vitro using non-clinically relevant models or treatment regimens, with many failing to progress to in vivo studies and even fewer to clinical application. The complexity of the host microbiota, in which commensals coexist with potential pathogens, provide a great challenge in developing antimicrobial agents against a particular microbial species. The presence of biological fluids that change surface chemistries poses yet another challenge. The ability of a drug to penetrate existing biofilms should be also considered, as this feature affects both potential cytotoxicity and antibacterial efficacy, and the potential for de novo emergence of antimicrobial resistance (owing to bacteria being subjected to sublethal anti biotic concentrations). Antibodies, aptamers or peptides that are linked to nano particles markedly enhance specificity, although higher costs and additional chemistry to produce multicomponent structures may be limiting factors. A key approach may be to trigger biofilm-disruptive activity in response to pathogenic microenvironments (for example, acidic pH, hypoxia or pathogen-derived metabolites). Thus, the biological effects can be tuned to specifically target the biofilm microenvironment, degrade the matrix and kill resident bacteria, thereby eradicating the pathogenic niche with precision and minimal cytotoxi city to surrounding tissues. Nevertheless, we noted a discrepancy between the research efforts on new technologies and commercialization. A concerted effort of chemists, engineers and biomedical researchers, combined with toxicology and safety studies, will help clinicians to assess the efficacy of these new technologies in clinical trials. However, the successful translation into the clinic depends not just on efficacy of the technology but also on regulatory agencies and industry efforts to bring it to the market. Future directions should focus on achieving maximal efficacy and specificity with minimal toxicity and longterm therapeutic effects along with industry partnerships to develop low-cost and practical formulations for clinical use.
